Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. - Ferrante, Marc; D'Haens, Geert; Jairath, Vipul; Danese, Silvio; Chen, Minhu; Ghosh, Subrata; Hisamatsu, Tadakazu; Kierkus, Jaroslaw; Siegmund, Britta; Bragg, Sonja Michelle; Crandall, Wallace; Durand, Frederick; et al. (Lancet, 2024)